From ESC 2024: M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation
Results of RESHAPE-HF2 suggest use of mitral transcatheter edge-to-edge repair (M-TEER) was more effective than optimal medical therapy alone for reducing cardiovascular event risk among patients with heart failure and moderate to severe mitral regurgitation ineligible for surgery.
Presented at the European Society of Cardiology (ESC) Congress 2024, results of the study indicate undergoing M-TEER was associated with a reduction in total hospitalizations for heart failure and cardiovascular death as well as improvements in quality of life.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
